Related Experiment Video

Updated: May 30, 2026

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
08:23

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

The safety and efficacy of hydroxycarbamide in infants with sickle cell anemia

Clare Wykes1, David C Rees

  • 1Department of Paediatric Haematology, King's College Hospital NHS Foundation Trust, Denmark Hill, London, SE5 9RS, UK.

Expert Review of Hematology
|August 2, 2011
PubMed

Insights

Hydroxycarbamide (hydroxyurea) treatment in infants with sickle cell anemia reduced pain events and hospitalizations but did not improve primary organ function endpoints. Adverse effects were minimal, suggesting a favorable safety profile.

Area of Science:

  • Pediatric Hematology
  • Sickle Cell Disease Research
  • Clinical Trials in Infants

Background:

  • The BABYHUG study was the first prospective randomized controlled trial evaluating hydroxycarbamide in infants with sickle cell anemia.
  • The trial aimed to assess the impact of hydroxycarbamide on organ function in this vulnerable population.
  • Nearly 200 infants were enrolled regardless of disease severity and followed for two years.

Discussion:

  • While primary endpoints (splenic function, glomerular filtration rate) were not met, hydroxycarbamide demonstrated significant clinical benefits.
  • These benefits included a reduction in painful events, dactylitis, acute chest syndrome, hospital admissions, and transfusion needs.
  • The observed adverse effects were infrequent, indicating a manageable safety profile for hydroxycarbamide in infants.

Key Insights:

  • Hydroxycarbamide therapy in infants with sickle cell anemia shows a positive impact on reducing disease-related complications.
  • The drug did not achieve the primary goals related to splenic function and kidney function in the studied timeframe.
  • The study provides crucial data on the efficacy and safety of hydroxycarbamide in very young sickle cell patients.

Outlook:

  • Further research may explore long-term organ function outcomes with hydroxycarbamide in sickle cell anemia.
  • The findings support considering hydroxycarbamide for symptom management in infants with sickle cell anemia.
  • Investigating optimal dosing and monitoring strategies for hydroxycarbamide in infants is warranted.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...